• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

Quality by design: slowly, but right and together

04.05.2017/in News /by eugeneqqq

International Conference on Harmonization Is a hugely influential organization that offers pharmaceutical industry new approaches to drug development and application process and amends old. Any action taken by ICH or any approved recommendation is readily recognized by regulators and governments worldwide and quickly becomes a set of laws and regulations. Back in 2008, Quality by Design (QbD) approach was proposed by ICH in its key guidances Q8, Q9 and Q10. QbD is an approach to development that begins with predefined objectives, product and development process should be clearly assessed on basis of modern science at the beginning of development with risk management strategies considered.

Obviously, such approach seemed logical and was readily implemented into practice by FDA and EMA. So, in 2011 joint program for the parallel assessment of applications containing Quality by Design (QbD) elements was launched. Recently EMA released a report about results of this collaboration where it comes to obvious conclusions that EMA-FDA collaboration in an assessment of QbD applications is mutually beneficial and tells that the agencies developed three sets of questions and answers that clarify some details.

From a regulatory point of view, victory over improprieties is achieved one more time, cooperation is, as always, beneficial and regulatory practices perspective is, not surprisingly, good.

But on the other hand, QbD approach brings some complications into pharma business. Every commercial organization wants to launch a manufacturing process as fast as possible. Yet, work in accordance with QbD strategy – designing and executing studies, then analyzing them to make sense of findings – can take more time before manufacturing can start. Also, QbD can be difficult to implement when operations are geographically or functionally fragmented. For some pharma companies, worldwide QbD acceptance might feel as a pressure because their operation procedures are just not evolved enough yet.

Nevertheless, all the potential issues that may arise during QbD implementation will only stimulate industry to get better. The final report on FDA and EMA cooperation concludes that cooperation will be continued, moreover, further points for joint activities are to be discovered. Also, experts from each other’s agencies will be continuously hosted.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals
cialis 100 mg gittigidiyor does glucotrust really work cialis hap cialis 20 mg kullanıcı yorumları regl geciktirici hap cialis 5 mg ne kadar süre kullanılır kamagra 100 mg fx15 resmi satış sitesi ankara escort bayan bursa escort bayan izmir escort bayan viagra antalya escort

CONTACT

4 + 1 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Revolutionary head transplant will take place in China in the end of 2017 The International Society for Pharmaceutical Engineering establishes its branch...
Scroll to top